

Contents

Foreword	XXVII
Industrial Requirement on Nanopharmacy Research	XXIX
Introduction	XXXI

Volume 1

Part One	Entry to the Nanopharmacy Revolution	1
1	History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry	3
	<i>Albertina Ariën and Paul Stoffels</i>	
1.1	Nanopharmaceuticals in Cancer Therapy	4
1.2	Nanoparticles Actively Using the Host Machinery	5
1.3	Nanopharmaceuticals for Oral Administration and Long-Acting Injectable Therapy	8
1.4	Bridging Future Nanomedicines to Commercialization	10
1.5	Future Outlook	11
	Acknowledgments	12
	References	12
2	Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare	17
	<i>Simon Sebastian Raesch, Marina Poettler, Christoph Alexiou, and Claus-Michael Lehr</i>	
2.1	Introduction	17
2.1.1	Setting the Stage	17
2.1.2	Definition and Size Aspects	18
2.1.3	Nanopharmacy: Interdisciplinary Medicine	19
2.2	Nanopharmacy Concepts to Improve the Safety and Efficacy of Medicines	20
2.2.1	Overcoming the Solubility Barrier	20
2.2.2	Controlling Drug Release	20
2.2.2.1	Sustained Release	21

2.2.2.2	Stimuli-Responsive Release	21
2.2.3	Overcoming Biological Barriers	22
2.2.3.1	Epithelial–Endothelial Barriers	23
2.2.3.2	Noncellular Barriers	27
2.2.4	Targeting	29
2.2.4.1	Active Targeting	30
2.2.4.2	Passive Targeting	30
2.3	Technical Realization of Nanopharmaceuticals	30
2.3.1	Nanosized APIs	31
2.3.2	Organic Nanocarriers	32
2.3.2.1	Lipid-Based Nanocarriers	32
2.3.2.2	Polymer-Based Nanocarriers	32
2.3.2.3	Protein-Based Nanoparticles	33
2.3.3	Inorganic Nanoparticles	33
2.4	Safety of Nanopharmaceuticals	34
2.5	Present and Future of Nanopharmacy	35
	References	37
3	The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs	43
	<i>Marilena Hadjidemetriou, Zahraa Al-Ahmady, Mariarosa Mazza, and Kostas Kostarelos</i>	
3.1	Introduction	43
3.2	First Generation of Nanopharmaceuticals: From Drug Molecules to Nanodrugs	45
3.2.1	Making New Therapies Happen: The Example of Nucleic Acid Therapeutics	47
3.2.1.1	Making Nanodrugs Smarter: Multifunctional Nanodrugs	49
3.3	Conclusion	55
	References	56
4	Understanding and Characterizing Functional Properties of Nanoparticles	63
	<i>Ester Polo, Valentina Castagnola, and Kenneth A. Dawson</i>	
4.1	Introduction	63
4.1.1	Key Concepts: Size Matters, Biological Interactions	65
4.1.2	Link Between Material Properties and Characterization for Differing Timescales of Biological Interaction	67
4.1.2.1	Early Times	67
4.1.2.2	Degradation of Surface	68
4.1.2.3	Long Timescales	69
4.1.2.4	Priorities	70
4.2	The Approach to Characterization	70
4.2.1	The Nature of Early-Stage Biological Recognition	70
4.2.1.1	Epitope and Recognition Motif Mapping	71

4.2.1.2	Forces, Dynamics, and Other Processes at Bio-Nano interface	71
4.2.2	The Nature of the Intracellular Bio-Nano Interface	74
4.2.3	The Future of the Bio-Nano Interface, Bionanoscience, and Nanomedicine	76
	References	77
5	Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine	81
	<i>Daniel Rosenblum and Dan Peer</i>	
5.1	Introduction	81
5.2	Precision Medicine	82
5.2.1	Precision Oncology	83
5.2.2	Therapeutic mAbs	83
5.2.3	Therapeutic Small-Molecules Inhibitors	84
5.2.4	Chimeric Antigen Receptors (CARs)	85
5.3	“OMICS” – New Era in Understanding Pathology	86
5.3.1	Next-Generation Sequencing (NGS)	86
5.3.2	The Identification of “Clear-Cut” Biomarkers Using State-of-the-Art Proteomics	87
5.3.3	Personal OMICS Profiling	88
5.3.4	Single-Cell Sequencing	89
5.4	Nanomedicine	90
5.4.1	Personalized Oncology Using Nanomedicine	90
5.4.1.1	Passive Tissue Targeting vs. Active Cellular Targeting	90
5.4.2	RNAi: A powerful Approach for Cancer Personalized Therapy	92
5.5	Future Outlook	93
	Acknowledgments	96
	References	96
Part Two	Fundamentals of Nanotechnology in Pharmacy	101
6	Nanostructures in Drug Delivery	103
	<i>Salma Nabil Tammam and Alf Lamprecht</i>	
6.1	Introduction	103
6.2	Nanocarrier Classification	103
6.2.1	Inorganic Nanostructures	104
6.2.2	Organic Nanostructures	106
6.2.2.1	Drug Nanocrystals	106
6.2.2.2	Matrix Systems	108
6.2.2.3	Vesicular Systems	112
6.3	Drug Loading and Release	116
6.3.1	Hydrophobic Drugs	117
6.3.2	Hydrophilic Drugs	119
6.3.3	Macromolecular Drugs	121

6.4	General Discussion and Conclusions	123
	References	124
7	Characterization Methods: Physical and Chemical Characterization Techniques	135
	<i>Sven Even F. Borgos</i>	
7.1	The Need for Nanomedicine-Specific Characterization	135
7.2	The Assay Cascade: From Basic Properties to Complex Interactions	136
7.3	Physicochemical Characterization of Pristine Nanoparticles	137
7.3.1	Size, Size Distribution, and Topology	137
7.3.1.1	Batch Particle Sizing Techniques	138
7.3.1.2	Single Particle Sizing Techniques	139
7.3.1.3	Separation- and Fractionation-Based Sizing Techniques	140
7.3.2	Surface Characteristics and Functionalization	142
7.3.2.1	Zeta (ζ) Potential	142
7.3.2.2	Chemical Surface Functionalization and Targeting	142
7.3.3	Composition and Purity	143
7.4	Characterization of Nanoparticles in the Biological Environment	144
7.4.1	Sterility and Endotoxin	145
7.4.2	Surface Adsorption: the Protein Corona	146
7.4.3	Drug Release	147
7.5	Conclusions and Future Outlook	149
	References	150
8	Nanoparticle Characterization Methods: Applications of Synchrotron and Neutron Radiation	157
	<i>Martha Brennich, Marité Cardenas, Hiram Castillo-Michel, Marine Cotte, V. Trevor Forsyth, Michael Haertlein, Simon A. J. Kimber, Geraldine Le Duc, Edward P. Mitchell, Adam Round, Murielle Salome, and Michael Sztucki</i>	
8.1	Advanced Characterization: Synchrotron Light and Neutron Sources	157
8.2	Application Examples	159
8.2.1	Synchrotron Micro-X-ray Fluorescence and Micro-X-ray Absorption Spectroscopy	160
8.2.2	Pair Distribution Function	163
8.2.3	Small-angle X-ray Scattering	164
8.2.4	Small-Angle Neutron Scattering and Neutron Reflectometry	167
8.3	Going Beyond Characterization Using Synchrotron X-rays: Nanoparticles for Diagnostic and Therapeutic Approaches	168
8.4	Looking Ahead and Conclusions	169
	Acknowledgments	170
	References	171

9	Overview of Techniques and Description of Established Processes	175
	<i>Jan Henrik Finke, Michael Juhnke, Arno Kwade, and Heike Bunjes</i>	
9.1	Introduction	175
9.2	Processing of Liquid Drug Carrier Formulations	176
9.2.1	Colloidal Lipid Emulsions	176
9.2.1.1	General Aspects and Composition	176
9.2.1.2	Preparation Process of Intravenous Fat Emulsions	177
9.2.1.3	Preparation of the Adjuvant Emulsion MF59	180
9.2.2	Liposomes	181
9.2.2.1	General Aspects and Composition	181
9.2.2.2	Preparation of Liposomal Dispersions	183
9.2.2.3	Drug Incorporation into Liposomes and Other Colloidal Lipid Structures	185
9.2.2.4	DepotFoam [®] Technology	187
9.2.2.5	Sterilization of Liposomes	188
9.2.2.6	Drying of Liposomal Dispersions	188
9.2.3	Polymeric Nanoparticles	189
9.2.3.1	General Aspects	189
9.2.3.2	Abraxane [®]	192
9.3	Drug Nanoparticles and Process Chains to Solid Formulations	192
9.3.1	Drug Particle Size-Determining Processes	193
9.3.1.1	Comminution Processes (Top-Down Methods)	193
9.3.1.2	Bottom-Up Processes	204
9.3.1.3	Hybrid/Combinative Methods	205
9.3.2	Drying Methods and Further Processing	207
9.3.2.1	Freeze-Drying	207
9.3.2.2	Spray-Drying	208
9.3.2.3	Spray-Coating, Granulation, and Pelletization	210
9.3.2.4	Other Conversion Methods	212
9.3.3	Marketed Products Containing Drug Nanoparticles	212
9.3.3.1	Rapamune [®]	214
9.3.3.2	Emend [®]	215
9.4	Industrial Status and Framework	215
9.5	Perspectives for Academia, Industry, and Regulatory Authorities	216
	References	217
10	Nanopharmacy: Exploratory Methods for Polymeric Materials	231
	<i>Kuldeep Bansal, Luana Sasso, Hiteshri Makwana, Sahar Awwad, Steve Brocchini, and Cameron Alexander</i>	
10.1	Introduction	231
10.2	Rationale for the Use of Polymers in Nanomedicines	232
10.3	Polymer Structures and Properties	234
10.3.1	Polymer Morphology	234
10.3.2	Polymer Structures for Drug Delivery – Micelles and Vesicles	236

10.4	Formulation of Copolymers into Micelles, Vesicles, and Nanoparticles	236
10.4.1	Investigational Formulations – Stimuli-Responsive Polymers	238
10.5	Conjugation of Polymers to Drugs and Proteins	240
10.5.1	Polymer–drug Conjugates	240
10.5.2	PEG-Protein Conjugates	242
10.5.3	Properties of PEGylated Proteins	242
10.5.4	Preparation of PEGylated Proteins	243
10.5.5	Moving Beyond Protein PEGylation	247
10.6	Recent Advances in Polymer Synthesis for Therapeutic Applications	248
10.6.1	Biodegradable Polymers for Nanomedicines	249
10.6.2	Classification of Biodegradable Polymers	249
10.6.2.1	Naturally Occurring Biodegradable Polymers for Nanomedicine	249
10.6.2.2	Synthetic Biodegradable Polymers for Nanomedicine	250
10.6.3	Mechanisms of Polycondensation Reactions	251
10.6.3.1	Fischer Esterification	251
10.6.3.2	Transesterification	251
10.6.4	Ring-Opening Polymerization	251
10.6.4.1	Anionic ROP	252
10.6.4.2	Cationic ROP	252
10.6.4.3	Coordination–Insertion ROP	252
10.6.5	Examples of Synthetic Polyesters as Investigational Nanomedicines	253
10.6.5.1	Poly(caprolactone)	253
10.6.5.2	Poly(anhydrides)	253
10.6.5.3	Poly(trimethylene Carbonate)	253
10.6.5.4	Polyesters in Development	254
10.6.5.5	Poly(esters) of Lactide and Glycolide	254
10.7	Controlled Radical Polymerization (CRP)	259
10.7.1	Atom Transfer Radical Polymerization (ATRP)	260
10.7.2	Reversible Addition Fragmentation Chain Transfer (RAFT) Polymerization	260
10.8	Concluding Remarks	260
	References	261
11	Overview and Presentation of Exploratory Methods for Manufacturing Nanoparticles/“Inorganic Materials”	271
	<i>Xavier Le Guevel</i>	
11.1	Introduction	271
11.2	Gold NPs	272
11.2.1	Different Shapes and Optical Properties	272
11.2.2	Conjugated (Covalent and Noncovalent)	276
11.2.3	Polymer/Polyelectrolyte Coating	277
11.2.4	Lipids	277

11.2.5	Composite	279
11.3	Magnetic NPs	279
11.3.1	Synthesis	279
11.3.2	Stabilization/Protection of Magnetic NPs	280
11.3.3	Hybrid Magnetic Nanosystem for Delivery	280
11.4	Metal Oxide NPs	282
11.4.1	Silica/Silicon	282
11.4.2	Calcium Phosphate, Hydroxyapatite	283
11.4.3	Others: Titanium Oxide and Aluminum Oxide	283
11.5	Others (Silver, Quantum Dots, and Lanthanides)	284
11.6	Conclusion and Perspective	285
	Acknowledgment	285
	References	285
12	Scale-Up and cGMP Manufacturing of Nanodrug Delivery Systems for Clinical Investigations	295
	<i>Mostafa Nakach and Jean-René Authelin</i>	
12.1	Introduction	295
12.2	Presentation of Major Manufacturing Processes of Different Nanodrug Delivery Systems	296
12.2.1	Process Including a Precipitation Step: The So-Called Bottom-Up Process	296
12.2.2	Process Including a Comminution Step: The So-Called Top-Down Process	297
12.2.2.1	Manufacturing of Nanocrystalline Suspension Using Direct Comminution	297
12.2.2.2	Manufacturing of Nanocrystalline, Nanoamorphous, or Nanopolymeric Suspension Using Emulsification Technique	298
12.2.2.3	Manufacturing of Lipid Emulsions	298
12.2.3	Manufacturing of Liposomes	299
12.2.4	Conversion of Nanosuspensions into Solid Intermediate for Downstream Processing into Final Drug Product	301
12.3	Nanodrug Delivery Systems as Marketed Products	302
12.4	Particle/Vesicle Size Reduction Technologies	302
12.4.1	High-Pressure Homogenization	302
12.4.1.1	Different High-Pressure Homogenizer Design	304
12.4.2	Stirred Bead Milling	306
12.4.2.1	Different Mill Designs	307
12.4.2.2	Conclusions: Size Reduction	307
12.5	Process Development and Scale-Down/Scale-Up Strategy	308
12.5.1	API x Case Study	309
12.5.1.1	Drug Product Definition	309
12.5.1.2	Study Context of the Laboratory-Scale Process	309
12.5.1.3	Scaling Up of the Bangham Manufacturing Technique	309
12.5.1.4	Development and Scaling Up of Direct Injection Method	311

12.5.1.5	Lessons Learned	318
12.5.2	Scale-Up and Scale-Down Strategies	318
12.5.2.1	Scaling Up of Bead Milling Technology	319
12.5.2.2	Scaling Up of High-Pressure Homogenization	319
12.5.2.3	Generic Development Methodology	320
12.6	Technological Concept for Manufacture of Drug Product for Human Use (GMP Unit)	322
12.6.1	Process Technology Configuration for Manufacturing of Nanocrystalline Suspension Using Top-Down Process	323
12.6.2	Process Technology Configuration for Manufacturing of Nanocrystalline Suspension Using Bottom-Up Process or for Nanoemulsion, Liposomes, or Polymeric Nanoparticles	324
12.6.3	Equipment Design Requirements	325
12.6.3.1	Equipment Sterilization	326
12.6.3.2	Equipment Cleaning	326
12.6.3.3	Equipment Drying	326
12.6.4	Facility Requirements	327
12.7	Conclusion	327
	References	327
13	Occupational Safety and Health	331
	<i>Thomas H. Brock</i>	
13.1	Nanomaterials at the Workplace	331
13.2	Legal Aspects	335
13.3	Management of Uncertainty	336
13.4	Risks of Nanomaterials for Researchers and Workers	336
13.5	Prudent Practices and Proven Concepts for Controlling Risks	338
13.5.1	Risk Assessment	338
13.5.2	Workplace Measurements	341
13.5.3	Protective Measures	344
13.6	Instruction and Training	351
13.7	Summary	352
	References	352

Volume 2

Part Three Development of Nanopharmaceuticals 355

14	Micro- and Nano-Tools in Drug Discovery	357
	<i>Andreas Dietzel, Monika Leester-Schädel, and Stephan Reichl</i>	
14.1	Introduction	357
14.2	General Concepts of Miniaturization	357
14.3	Micro- and Nanofabrication	359
14.3.1.1	Photolithography	359
14.3.1.2	Depth Lithography	360

- 14.3.1.3 Soft Lithography 360
- 14.3.1.4 Wet Chemical and Dry Etching 360
- 14.3.1.5 Thin Film Deposition 362
- 14.3.1.6 Bonding Techniques 363
- 14.3.1.7 3D Printing 364
- 14.3.1.8 Microelectrical Discharge Machining (μ EDM) 365
- 14.3.1.9 Laser Fabrication 366
- 14.3.1.10 Surface Functionalization 366
- 14.4 Nanoformulation 367
 - 14.4.1 High-Pressure Nanonization Systems 367
 - 14.4.2 Low-Pressure Nanonization Systems 369
- 14.5 Organ-on-a-Chip 372
 - References 375

- 15 Computational Predictive Models for Nanomedicine 379**
Marco Siccardi, Alessandro Schipani, and Andrew Owen
 - 15.1 Introduction 379
 - 15.2 Molecular Modeling in Nanomedicine 381
 - 15.3 Computational Approaches for Predicting Nanotoxicology 384
 - 15.4 Simulation of Nanoparticle Pharmacokinetics 386
 - 15.4.1 Nanoparticle Absorption 386
 - 15.4.2 Nanoparticle Distribution 388
 - 15.4.3 Nanoparticle Elimination 389
 - 15.4.4 Physiologically Based Pharmacokinetic Models (PBPK) 389
 - 15.4.5 Integration of Experimental Data in PBPK Models 391
 - 15.4.6 Examples of PBPK Models 391
 - 15.4.7 Limitations of the PBPK Approach 394
 - 15.4.8 Future Perspective of PBPK Modeling 394
 - 15.5 Conclusion 395
 - References 397

- 16 Drug Targeting in Nanomedicine and Nanopharmacy: A Systems Approach 403**
Jingwei Shao, Lisa McConnachie, and Rodney J.Y. Ho
 - 16.1 Introduction 403
 - 16.2 A Systems Approach to Drug Delivery and Drug Targeting 405
 - 16.3 Current Nanomedicine Products 407
 - 16.4 Transformation of a Discovery of Disease Target to a Therapeutic Product 410
 - 16.5 The Role of Targeted Nanoformulations and a Systems Approach in Drug Development 412
 - 16.6 Targeting Drugs to Sites of Action 413
 - 16.7 A Size-Dependent Targeting to Tissues and Cells 414
 - 16.8 Ligand–Receptor-Based Targeting: Active Drug Targeting 417
 - 16.8.1 Target Selected Delivery of a Toxin with an Antibody 418

- 16.8.2 Targeting of Drug in Lipid Nanoparticles Based on Ligand–Receptor Interactions 420
- 16.9 Conclusions and Future Prospects 421
References 422
- 17 Nanoparticle Toxicity: General Overview and Insights Into Immunological Compatibility 425**
Marina A. Dobrovolskaia
- 17.1 Introduction 425
- 17.2 Systemic Toxicity 427
- 17.3 Pulmonary Toxicity 428
- 17.4 Cutaneous Toxicity 431
- 17.5 Immunotoxicity 432
- 17.6 Unintended Presence of Nanosized Materials in Pharmaceutical Formulations 434
- 17.7 Conclusion 435
Acknowledgments 435
References 436
- 18 An Overview of Nanoparticle Biocompatibility for Their Use in Nanomedicine 443**
Matthew S.P. Boyles, Leigh G. Powell, Ali Kermanizadeh, Helinor J. Johnston, Barbara Rothen-Rutishauser, Vicki Stone, and Martin J.D. Clift
- 18.1 Introduction 443
- 18.2 Nanomedicine 444
- 18.3 Biocompatibility of Nanoparticles for Medical Application 445
- 18.3.1 Metal-Based Nanoparticles 446
- 18.3.1.1 Methods of Targeting Metal NPs 448
- 18.3.2 Carbon-Based Nanoparticles 450
- 18.3.3 Polymer-Based Nanoparticles 453
- 18.3.4 Biological-Based Nanoparticles 456
- 18.4 Summary 458
References 459
- 19 Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles – The Translational Challenge 469**
Rachel Tyson, Leah Osaë, Andrew J. Madden, and Andrew T. Lucas, and William C. Zamboni
- 19.1 Introduction 469
- 19.2 Nanoparticle Formulations 469
- 19.3 Pharmacokinetic Characterization 470
- 19.4 Mononuclear Phagocyte System 470
- 19.5 Delivery of CMA in Tumor 472
- 19.6 Methods to Target Brain Tumors 475
- 19.7 Physical Characteristics 477

- 19.7.1 Particle Size 477
- 19.7.2 Particle Shape 478
- 19.7.3 Surface Modification 478
- 19.7.4 Surface Charge 479
- 19.7.5 Particle Dose 480
- 19.8 The Effect of MPS on CMA PK and PD 480
- 19.9 Age 483
- 19.10 Gender 486
- 19.11 Tissue and Organ Effects 487
 - 19.11.1 Body Habitus 487
 - 19.11.2 Presence of Liver Tumors 487
- 19.12 Drug–Drug Interactions 488
- 19.13 Prior Treatment 489
- 19.14 Translational Challenges 490
- 19.15 Future Perspectives on PK and PD 491
- References 492

- 20 Regulatory Issues in Nanomedicines 497**
Marisa Papaluca, Falk Ehmann, Ruben Pita, and Dolores Hernan
- 20.1 Nanomedicines and the Pharmaceuticals Regulatory Framework in Europe 497
- 20.2 The European Medicines Agency and Nanomedicines 499
- 20.3 Is It Important to Define Nanomedicines? 501
- 20.4 Communicating About Nanomedicines 503
- 20.5 Liposomal Formulations: State of Play at the EMA 504
- 20.6 Nanosimilar Colloidal Intravenous Iron-Based Preparations 511
- 20.7 International Landscape and Convergence on Nanomedicines 514
- 20.8 Conclusions and Way Forward 517
- References 518

- 21 Social Studies of Nanopharmaceutical Research 521**
Michael Schillmeier
- 21.1 Engaging with Ethical, Legal, and Social Implications of Nanoresearch 521
- 21.2 Nanopharmacy and the “Culture of Promise” 522
- 21.3 From “Science Meets Society” to Translation as a Social Process 523
- 21.4 Metaphors and Nanopharmacy 525
- 21.5 Nanopharmacy and “Personalized Medicine” 526
- 21.6 Concluding Remarks 528
- References 529

Part Four Pharmaceutical Applications of Nanomaterials 533

- 22 Nanoparticles for Imaging and Imaging Nanoparticles: State of the Art and Current Prospects 535**
Thomas Maldiney and Nathalie Mignet
- 22.1 Introduction 535
- 22.2 Conception of Nanotechnologies for Imaging 536
- 22.2.1 Nanoparticles Designed for Optical Imaging 536
- 22.2.2 Particles Designed for Ultrasound Imaging 540
- 22.2.3 Particles Designed for Magnetic Resonance Imaging 543
- 22.3 *In Vivo* Nanoparticle Imaging to Gain Insight into Nanomedicine Biodistribution and Stability 544
- 22.3.1 Nanoparticle Biodistribution 544
- 22.3.2 Imaging Nanoparticles to Optimize Surface and Size with Reference to Their Biodistribution and Clearance 545
- 22.3.3 Imaging Nanoparticle to Optimize Their Intrinsic Stability 547
- 22.4 Translational Interest of Nanoparticles for Medical Imaging 548
- 22.4.1 Macrophage Imaging by Nanoparticle Uptake 548
- 22.4.2 Blood Pool Agent 549
- 22.4.3 Targeted Nanoparticles 550
- 22.5 Conclusion 553
- References 553
- 23 Nanoparticle-Based Physical Methods for Medical Treatments 561**
Christine Ménager
- 23.1 Photothermal Therapy 561
- 23.1.1 Gold Nanoparticles 561
- 23.1.2 Carbon Nanomaterials 564
- 23.1.2.1 Carbon Nanotubes 564
- 23.1.2.2 Nanographene 565
- 23.2 Photodynamic Therapy 565
- 23.2.1 TiO₂ Nanoparticles 565
- 23.2.2 Upconversion Nanoparticles (UCN) 567
- 23.3 Magnetic Hyperthermia 567
- 23.3.1 Magnetic Iron Oxide Nanoparticles 568
- 23.4 Radiotherapy 571
- 23.4.1 Hafnium Oxide Nanoparticles 571
- 23.5 Sonodynamic Therapy 572
- 23.6 Cryosurgery 573
- 23.7 Future Perspectives 574
- References 575

- 24 Nanodrugs in Medicine and Healthcare: Oral Delivery 579**
Alejandro Sosnik
- 24.1 General Aspects and Challenges of Oral Drug Delivery 579
- 24.2 Pure Drug Micronization as a Conceptual Preamble to More Complex Drug Delivery 580
- 24.3 Nanotechnology Platforms for Improved Oral Drug Delivery 581
- 24.3.1 Pure Drug Nanoparticles 581
- 24.3.2 Dendrimers and Other Branched Nanocarriers 585
- 24.3.3 Polymeric Micelles 585
- 24.3.4 Nanoemulsions 587
- 24.3.5 Solid Lipid Nanoparticles 587
- 24.3.6 Polymeric Nanoparticles 590
- 24.4 Conclusive Remarks 591
- Acknowledgments 591
- References 591
-
- 25 Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents 603**
Keren Turjeman and Yechezkel Barenholz
- 25.1 A Short Relevant Background on Inflammatory and Autoimmune Diseases 603
- 25.2 Drug Delivery Systems (DDS) Based on Nanoparticles (NP) for the Treatment of Diseases That Involve Inflammation 605
- 25.3 Glucocorticosteroid as Anti-Inflammatory Agents 607
- 25.4 Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents 609
- 25.5 Methods for Loading Drugs into Liposomes 610
- 25.5.1 Passive Drug Loading 610
- 25.5.2 Remote (Active) Drug Loading 611
- 25.6 Comparing Various Approaches Used for Formulating Liposomal GCs 612
- 25.7 The Use of Liposomes Loaded with Steroids as Anti-Inflammatory Agents: A Brief Historical Perspective 615
- 25.8 Lessons Learned from Experimental Animal Models of Diseases That Involve Inflammation 618
- 25.8.1 Pharmacokinetics (PK) and Biodistribution (BD) Advantages of Steroidal Nanodrugs 619
- 25.8.2 NSSL-Based Steroidal Nanodrugs Improve Significantly the Anti-Inflammatory Therapeutic Efficacy over the Same Steroids Given “As Is” 623
- 25.8.3 Treatment with Liposomal Steroids Affects Cytokines Secretion and Tissue Pathology 624

- 25.8.4 Replacing Steroids with Nanosteroidal Drugs Results in Reduced Toxicity 624
- References 625

26 Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination 633

Christel C. Müller-Goymann and Mukta Paranjpe

- 26.1 Introduction 633
- 26.2 Different Routes of Administration 634
 - 26.2.1 Pulmonary Route 634
 - 26.2.2 Nasal Route 635
 - 26.2.3 Ophthalmic Route 636
 - 26.2.4 Vaccination 637
- 26.3 Different Types of Nanoparticles for Different Routes of Administration 638
- 26.4 Manufacturing Processes of Nanoparticles 638
- 26.5 Different Diseases Targeted Via Nanoparticle-Based Drug Delivery Systems 640
 - 26.5.1 Pulmonary Diseases 640
 - 26.5.2 Nasal Diseases 640
 - 26.5.3 Ophthalmic Diseases 640
 - 26.5.4 Vaccination 641
- 26.6 Challenges Faced in Formulation Development of Nanoparticle-Based Systems 641
- References 642

27 Neurodegenerative Diseases – Alzheimer’s Disease 649

Maria Gregori and Francesca Re

- 27.1 Introduction 649
- 27.2 Diagnosis 650
 - 27.2.1 Detection of Amyloid Plaques 650
 - 27.2.2 Detection of AD Biomarkers 651
- 27.3 Therapy of Alzheimer’s Disease 653
 - 27.3.1 Current Therapies 653
 - 27.3.2 Latest Therapeutic Directions 654
 - 27.3.3 Future Directions: Nanomedicine 655
- References 656

Part Five The Nanopharmaceutical Market 661

28 A Practical Guide to Translating Nanomedical Products 663

Raj Bawa

- 28.1 From the Laboratory to the Clinic: Overcoming the Valley of Death 666

28.2	Irreproducible Preclinical Research: A Bottleneck for Translation? 673
28.3	Protecting Inventions via Patents: The Cornerstone of Translation 678
28.4	Terminology and Nomenclature: Lost in Translation 680
28.5	Gaps in Regulatory Guidance 682
28.6	Conclusions and Outlook 683
28.7	Disclosures and Conflict of Interest 694
	References 694
29	Development and Commercialization of Nanocarrier-Based Drug Products 697
	<i>Marianne Ashford</i>
29.1	Drivers for New Medicines 697
29.2	Current Marketed Nanomedicines 699
29.2.1	Amphotericin B Liposomal Products 699
29.2.2	Doxil 700
29.2.3	Other Liposomal Products in Oncology 702
29.2.4	ABRAXANE® 702
29.2.5	Genexol-PM 703
29.2.6	Pegylated Proteins 703
29.2.7	Antibody Drug Conjugates 704
29.3	Developing Nanomedicines 705
29.3.1	The Development Process 705
29.3.2	Improving Translation of Nanomedicines into Clinical Use 706
29.3.2.1	Lessons Learnt from Traditional Research and Development 706
29.3.2.2	Support from Specialist Groups 708
29.3.3	Preclinical Development 709
29.3.3.1	<i>In Vitro</i> Preclinical Development Testing 709
29.3.3.2	<i>In Vivo</i> Preclinical Development 712
29.3.3.3	Formulation and Process Optimization 714
29.3.3.4	Analytical Considerations 719
29.3.3.5	Lessons Learnt from NCL 719
29.3.4	Regulatory Considerations 720
29.4	Commercialization of Nanomedicines 722
29.4.1	Nanotechnology Investment 723
29.4.2	The Nanomedicine Market 724
29.4.3	Challenges and Initial Solutions for Nanomedicine Commercialization 726
29.4.4	Key Players in Nanomedicines 730
29.5	Conclusions 732
	References 732

30	Future Outlook of Nanopharmacy: Challenges and Opportunities	735
	<i>Dan Peer and Marcel Van de Voorde</i>	
30.1	Matching the NC's Delivery Mode of Action (MoA) to the Tumor Type	736
30.2	Nonpredictive Animal Models	737
30.3	The Lack of Reliable Techniques that can Efficiently Characterize NCs and Measure their Stability in the Human Body	737
30.4	The Challenge of Scaling Up NCs	738
	References	740
	Index	743